NOTCH1 and metastatic neoplasm: Of newly diagnosed CRC patients, 40–50% will develop metastasis; based on the evidence that Notch1 promotes tumorigenesis and the spread of metastatic disease in CRC, targeting Notch1 signaling gains momentum for the treatment of CRC.